FDA Recalls Akorn PAREMYD Eye Medication for Manufacturing Quality Deviations
Akorn, Inc. is voluntarily recalling 51,601 bottles of PAREMYD eye medication nationwide due to manufacturing process deviations. The firm initiated the recall in October 2022.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with voluntary firm-initiated withdrawal for manufacturing process deviations. No reported illnesses or injuries; consistent with precautionary manufacturing-quality recalls.
Plain-English summary
Akorn, Inc. is recalling PAREMYD (hydroxyamphetamine hydrobromide/tropicamide ophthalmic solution) 1%/0.25%, a prescription eye medication supplied in 15 mL dropper bottles. The recall affects 51,601 bottles distributed nationwide.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. The firm voluntarily initiated the recall beginning October 13, 2022, and the FDA classified it as a Class II recall on January 13, 2023.
The affected lot numbers and expiration dates are: Lot 0B55A (expires 1/31/2023), Lots 0D16A and 0D23A (expire 3/31/2023), Lot 0E51A (expires 4/30/2023), and Lot 1C46A (expires 2/29/2024). Additional information about the recall is available from the FDA and Akorn, Inc.
The recalled product
- Product
- PAREMYD (hydroxyamphetamine hydrobromide/ tropicamide ophthalmic solution) 1%/0.25%, 15 mL per dropper bottle, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. NDC: 17478-704-12
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
- Hazard
- Affected units
- 51,601
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot: 0B55A
- EXP 1/31/2023
- 0D16A
- 0D23A
- EXP 3/31/2023
- 0E51A
- EXP 4/30/2023
- 1C46A
- EXP 2/29/2024
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 27 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 27 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- HighAkorn Tropicamide Ophthalmic Solution Recalled for Manufacturing Quality Deviations
FDA (Drugs) · 2023-06-07
- ModerateTropicamide Ophthalmic Solution Recalled by Akorn for CGMP Deviations
FDA (Drugs) · 2023-06-07
- ModerateAkorn Recalls Proparacaine Hydrochloride Ophthalmic Solution Due to Chemical Contamination
FDA (Drugs) · 2020-07-22
- HighFDA Recalls Apraclonidine Ophthalmic Solution Due to Manufacturing Compliance Failures
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Akorn Gonak Eye Drops for Manufacturing Deviations
FDA (Drugs) · 2023-06-07
- SevereAkorn Recalls Phenylephrine Ophthalmic Solution Due to Sterility Concerns
FDA (Drugs) · 2019-10-09